V

Vanda Pharmaceuticals
D

VNDA

4.42500
USD
0.07
(1.49%)
مغلق
حجم التداول
10,422
الربح لكل سهم
-0
العائد الربحي
-
P/E
-15
حجم السوق
258,013,537
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
أصول ذات صلة
    A
    ACAD
    1.305
    (7.33%)
    19.110 USD
    A
    ALKS
    1.540
    (5.10%)
    31.760 USD
    AMGN
    AMGN
    4.27
    (1.56%)
    277.86 USD
    AZN
    AZN
    0.405
    (0.59%)
    68.610 USD
    BMY
    BMY
    2.065
    (3.62%)
    59.140 USD
    C
    CRBP
    -0.540
    (-4.76%)
    10.810 USD
    GILD
    GILD
    -0.110
    (-0.12%)
    92.910 USD
    I
    INCY
    0.120
    (0.17%)
    72.540 USD
    J
    JAZZ
    1.750
    (1.45%)
    122.570 USD
    S
    SGMO
    0.03500
    (3.03%)
    1.19000 USD
    المزيد
الأخبار
المقالات

العنوان: Vanda Pharmaceuticals

القطاع: Healthcare
الصناعة: Biotechnology
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products, HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS), Fanapt for the treatment of schizophrenia and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from HETLIOZ product sales.